PATENTS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc Belotti et al.)
) Art Unit: 1614
Serial No. 10/796,691)
) Examiner: Not yet assigned
Filed: March 8, 2004)

For: Methods and Apparatus for Creating Particle Derivatives of HDL With Reduced Lipid Content

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 16, 2004

Matthew L. Collins

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each Non-U.S. Patent cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Khn Ř. McDonald, Ph.D.

Reg. No. 42,830

KILPATRICK STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500

Our Docket: 13131-0331 (44378/293531)

ATLLIB02 165181.1

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form ADEMAS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 9

Cor	nplete if Known
Application Number	10/796,691
Filing Date	March 8, 2004
First Named Inventor	Bellotti
Group Art Unit	1614
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0331 (44378/293531)

			U.S. PATENT DOCUMENT	rs	
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
#110013	1	3,647,624	Evenson	03-07-1972	
	2	3,958,939	Jones	05-25-1976	
	3	3,983,008	Shinozaki et al.	09-28-1976	
	4	3,989,466	Pan	11-02-1976	
	5	4,025,423	Stonner et al.	05-24-1977	
	6	4,103,685	Lupien et al.	08-01-1978	
	7	4,124,509	Iijima et al.	11-07-1978	
_	8	4,235,602	Meyer et al.	11-25-1980	
· · · · · · · · · · · · · · · · · · ·	9	4,258,010	Rozsa et al.	03-24-1981	
	10	4,350,156	Malchesky et al.	09-21-1982	
	11	4,391,711	Jackson et al.	07-05-1983	1 000 000000000000000000000000000000000
	12	4,402,940	Nose et al.	09-16-1983	
	13	4,435,289	Breslau	03-06-1984	
	14	4,481,189	Prince	11-06-1984	10.00 - 10.00 - 10.00 - 10.00
	15	4,522,809	Adamowicz et al.	06-11-1985	
	16	4,540,401	Marten	09-10-1985	
	17	4,540,573	Neurath et al.	09-10-1985	
	18	4,591,505	Prince	05-27-1986	
	19	4,613,501	Horowitz	09-23-1986	-
	20	4,615,886	Purcell et al.	10-07-1986	
	21	4,643,718	Marten	02-17-1987	
	22	4,645,512	Johns	02-24-1987	
	23	4,647,280	Maaskant et al.	03-03-1987	
	24	4,648,974	Rosskopf et al.	03-10-1987	
	25	4,668,398	Silvis	05-26-1987	
- - -	26	4,671,909	Torobin	09-09-1987	
	27	4,676,905	Nagao et al.	06-30-1987	
	28	4,680,320	Uku et al.	07-14-1987	
· · · · · · · · · · · · · · · · · · ·	29	4,696,670	Ohnishi et al.	09-29-1987	
	30	4,832,034	Pizziconi et al.	05-23-1989	
	31	4,836,928	Aoyagi et al.	06-06-1989	
	32	4,879,037	Utzinger	11-07-1989	
	33	4,895,558	Cham	01-23-1990	
-	34	4,908,354	Seidel et al.	03-13-1990	
	35	4,909,940	Horowitz et al.	03-20-1990	
	36	4,909,942	Sato et al.	03-20-1990	
	37	4,923,439	Seidel et al.	05-08-1990	
	38	4,935,204	Seidel et al.	06-19-1990	
	39	4,966,709	Nose et al.	10-30-1990	

Examiner		Date	
Signature		Considered	

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 2 of 9

Cor	nplete if Known
Application Number	10/796,691
Filing Date	March 8, 2004
First Named Inventor	Bellotti
Group Art Unit	1614
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0331 (44378/293531)

				U.S. PATENT DOCUMENT	ΓS	
Examiner Initials	Cite No.1	U.S. Patent	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
initials	40	5,026,479	(lj known)	Bikson et al.	06-25-1991	r igures Appear
	41	5,080,796		Nose et al.	01-14-1992	
<u> </u>	42	5,089,602		Isliker et al.	02-18-1992	
	43	5,112,956		Tang et al.	05-12-1992	
	44	5,116,307	-	Collins	05-26-1992	
	45	5,152,743		Gorsuch et al.	10-06-1992	
	46	5,187,010		Parham et al.	02-16-1993	
	47	5,203,778		Boehringer	04-20-1993	
	48	5,211,850		Shettigar et al.	05-18-1993	
	49	5,236,644		Parham et al.	08-17-1993	
	50	5,256,767		Salk et al.	10-26-1993	
	51	5,258,149		Parham et al.	11-02-1993	
	52	5,279,540	-	Davidson	01-18-1994	
	53	5,301,694		Raymond et al.	04-12-1994	
	54	5,354,262		Boehringer et al.	10-11-1994	
	55	5,391,143		Kensey	02-21-1995	
	56	5,393,429		Nakayama et al.	02-28-1995	
	57					
	1	5,401,415		Rauh et al.	03-28-1995	
	58	5,418,061		Parham et al.	05-23-1995	
	59	5,419,759		Naficy	05-30-1995	
	60	5,424,068		Filip	06-13-1995	
	61	5,476,715		Otto	12-19-1995	W
	62	5,484,396		Naficy	01-16-1996	
	63	5,496,637		Parham et al.	03-05-1996	
	64	5,523,096		Okarma et al.	06-04-1996	
	65	5,634,893		Rishton	06-03-1997	
	66	5,637,224		Sirkar et al.	06-10-1997	
	67	5,652,339		Lerch et al.	07-29-1997	
	68	5,679,260		Boos et al.	10-21-1997	
	69	5,698,432		Oxford	12-16-1997	
	70	5,707,673		Prevost et al.	01-13-1998	
	71	5,719,194		Mann et al.	02-17-1998	
	72	5,744,038		Cham	04-28-1998	
	73	5,753,227		Strahilevitz	05-19-1998	
	74	5,853,725		Salk et al.	12-29-1998	
	75	5,855,782		Falkenhagen et al.	01-05-1999	
	76	5,858,238		McRea et al.	01-12-1999	
	77	5,877,005		Castor	03-02-1999	
-	78	5,885,578		Salk et al.	03-23-1999	

Examiner	Date	
Signature	Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3 of 9

Cor	nplete if Known
Application Number	10/796,691
Filing Date	March 8, 2004
First Named Inventor	Bellotti
Group Art Unit	1614
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0331 (44378/293531)

		U.S. Patent Document	U.S. PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines, Where
Examiner Initials	Cite No.1	Number (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear
	79	5,895,650	Salk et al.	04-20-1999	
	80	5,911,698	Cham	06-15-1999	
	81	5,916,806	Salk et al.	06-29-1999	· · · · · · · · · · · · · · · · · · ·
•	82	5,919,369	Ash	07-06-1999	
	83	5,928,930	Salk et al.	07-27-1999	
	84	5,948,441	Lenk et al.	09-09-1999	
	85	5,980,478	Gorsuch et al.	11-09-1999	
	86	6,017,543	Salk et al.	01-25-2000	
	87	6,022,333	Kensev	02-28-2000	
	88	6,037,458	Hirai et al.	03-14-2000	
	89	6,039,946	Strahilevitz	03-21-2000	
	90	6,080,778	Yankner et al.	06-27-2000	
	91	6,127,370	Smith et al.	10-03-2000	
	92	6,136,321	Barrett et al.	10-24-2000	
	93	6,139,746	Kopf	10-31-2000	
	94	6,171,373	Park et al.	01-09-2001	
	95	6,193,891	Kent et al.	02-27-2001	
	96	6,264,623	Strahilevitz	07-24-2001	-
	97	6,309,550	Iverson et al.	10-30-2001	
	98	6,337,368	Kobayashi et al.	01-08-2002	····
	99	6,440,387	Yankner et al.	08-27-2002	
•	100	6,472,421	Wolozin	10-29-2002	· - · · · ·
	101	6,706,008	Vishnoi et al.	03-16-2004	
	102	2001/0028895	Bisgaier et al.	10-11-2001	
	103	2002/0055529	Bisgaier et al.	05-09-2002	
	104	2002/0081263	Yankner et al.	06-27-2002	<u> </u>
	105	2002/0107173	Friedhoff et al.	08-08-2002	
	106	2002/0183379	Yankner et al.	12-05-2002	
	107	2002/0188012	Bisgaier et al.	12-12-2002	
-	108	2003/0018013	Dasseux et al.	01-23-2003	
	1				
			-		
				-	
					
	 				

	· ·			
i		l	ļ	
	Examiner	 	Date	
		<u> </u>	Date	
	Signature	!	Considered	
		1	, Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

Examiner

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet of | 9

Cor	nplete if Known
Application Number	10/796,691
Filing Date	March 8, 2004
First Named Inventor	Bellotti
Group Art Unit	1614
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0331 (44378/293531)

Examiner Initials	FORE				FORE	IGN PATENT DOCUMENTS			
Cited No. Office Number Number Relevant Relevant Relevant Figures		Foreign Patent Document			ocument		Date of Publication of	Pages, Columns, Lines,	i,
110 DE 29 44 138		<u> </u>	Office ³			Applicant of Cited Document	MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
111 DE 31 18 072 A1 Heuck 11-25-1982 112 DE 32 13 390 A1 Schurek, et al. 10-20-1983 113 DE 33 10 263 A1 Fresenius AG 09-27-1984 114 EP 0 036 283 A2 Davy Mckee Minerals & 09-23-1981 Metals Metals 115 EP 0 267 471 A1 Pennwalt Corporation 05-19-1988 116 FR 2 571 971 A1 Haas Thierry 04-25-1986 117 JP 127104 Shinriyoushiyo 01-10-1980 118 JP 277303 Tenkaidou 10-26-1993 119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 0		109							
112 DE 32 13 390 A1 Schurek, et al. 10-20-1983 113 DE 33 10 263 A1 Fresenius AG 09-27-1984 114 EP 0 036 283 A2 Davy Mckee Minerals & 09-23-1981 Metals Metals 115 EP 0 267 471 A1 Pennwalt Corporation 05-19-1988 116 FR 2 571 971 A1 Haas Thierry 04-25-1986 117 JP 127104 Shinriyoushiyo 01-10-1980 118 JP 277303 Tenkaidou 10-26-1993 119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 <		110	DE	29 44 138	Al	Technicon Gmbh	06-11-1981		
113 DE 33 10 263		111	DE	31 18 072	Al	Heuck	11-25-1982		
114 EP 0 036 283		112	DE	32 13 390	A1	Schurek, et al.	10-20-1983		
Metals Metals		113	DE	33 10 263	A1	Fresenius AG	09-27-1984		
116 FR 2 571 971 A1 Haas Thierry 04-25-1986 117 JP 127104 Shinriyoushiyo 01-10-1980 118 JP 277303 Tenkaidou 10-26-1993 119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		114	EP	0 036 283	A2		09-23-1981		
116 FR 2 571 971 A1 Haas Thierry 04-25-1986 117 JP 127104 Shinriyoushiyo 01-10-1980 118 JP 277303 Tenkaidou 10-26-1993 119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		115	EP	0 267 471	A1	Pennwalt Corporation	05-19-1988		
117 JP 127104 Shinriyoushiyo 01-10-1980 118 JP 277303 Tenkaidou 10-26-1993 119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		116	FR	2 571 971	A1		04-25-1986		
118 JP 277303 Tenkaidou 10-26-1993 119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		117	JP	127104			01-10-1980		
119 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		118	JP				10-26-1993		
120 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		119	SU		A		09-30-1984		
121 WO 95/03840 A1 The University of Queensland 02-09-1995 122 WO 99/38498 A1 Warner-Lambert Company 08-05-1999 123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002									
123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		121	WO	95/03840	A1	The University of Queensland	02-09-1995		
123 WO 01/45718 A1 Aruba International Pty Ltd. 06-28-2001 124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of 02-07-2002 California Californi		122	WO	99/38498	A1	Warner-Lambert Company	08-05-1999		
124 WO 01/56579 A1 Esperion Therapeutics, Inc. 08-09-2001 125 WO 02/010768 A3 Regents of University of California 02-07-2002 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		123	WO	01/45718	A1		06-28-2001		
125 WO 02/010768 A3 Regents of University of California 02-07-2002 California 126 WO 02/062824 A2 Andrx Corporation 08-15-2002		124	WO	01/56579	A1		08-09-2001		
	_	125	WO	02/010768	A3	Regents of University of	02-07-2002		
		126	WO	02/062824	A2	Andrx Corporation	08-15-2002		
		127	WO	02/30863	A2		04-18-2002	····	
Image: Control of the contro									
									
									_
							·		
									\top
								<u> </u>	1
					-		<u> </u>		
		_					-		1-
							-		1
						-			
									+
									\top
		-	 						1
									
		<u> </u>		<u> </u>		I	_l		

Date Signature Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

			Complete if Known		
Substitute for Form 1449/A/PTO			Application Number	10/796,691	
		ON DISCLOSURE	Filing Date	March 8, 2004	
		ON DISCLOSURE	First Named Inventor	Bellotti	
	STATEMEN	T BY APPLICANT	Group Art Unit	1614	
(use as many sheets as necessary			Examiner Name	Not yet Assigned	
Sheet	5	of 9	Attorney Docket Number	13131-0331 (44378/293531)	

Examiner Coling Coling			OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	,		
Agnese, et al., Clinical Biochemistry, Evaluation of Four Reagents for Delipidation of Serum, 16, 98-100, (1983) Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979) Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002) Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989) Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbits, 85, 1234-1241 (1990) Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996) 134 Biocm, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of In Vivo Models to Study the Rote of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Ginicial Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)			item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²		
Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979) 130 Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002) 131 Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989) 132 Badimon, et al., J. Clinical Investigation, Regression of Altherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241 (1990) 133 Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996) 134 Bioom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 26, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 198-206. (1981)	1	128				
130 Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002) 131 Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989) 132 Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241 (1990) 133 Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996) 134 Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 26, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	1	129	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing			
 76 (14), 6919-6928. (July 2002) 131 Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989) 132 Badimon, et al., J. Clinical Investigation, Regression of Altherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241 (1990) 133 Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996) 134 Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of in Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca²⁺, 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981) 			Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)			
Cholesterol-Fed Rabbits, 60, 455-461. (1989) 132 Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241 (1990) 133 Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996) 134 Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of σ- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	1	130				
the Cholesterol-Fed Rabbit, 85, 1234-1241 (1990) Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996) 134 Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum , 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	1	131				
Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum , 14, 119-125. (abstract only) (June 1981) Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003) Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of <i>σ</i> - and <i>β</i> -Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)						
serum , 14, 119-125. (abstract only) (June 1981) 135 Burns et al., Neurochem Res, Use of In Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease 28, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of <i>α</i> - and <i>β</i> -Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	133 Barres et al., Science, Cholesterol - Making or Breaking the Synapse, 294, 1296/1297. (1996)					
28, 979-86. (abstract only) (July 2003) 136 Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of <i>α</i> - and <i>β</i> -Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	1	134				
Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976) 137 Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	1	135				
176-181. (1976) 138 Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	1	136				
Delipidation, 22, 305-309. (1976) 139 Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)		137				
	1	138				
	1	139	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)			

Considered

Signature

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/796,691 **Filing Date** March 8, 2004 INFORMATION DISCLOSURE First Named Inventor Bellotti STATEMENT BY APPLICANT Group Art Unit 1614 (use as many sheets as necessary **Examiner Name** Not yet Assigned Sheet 6 9 Attorney Docket Number 13131-0331 (44378/293531) of |

F	C:1-	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7
	140	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
	141	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
	142	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid	
		Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	
	143	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns, 11, 61-70. (1996)	
	144		
	144	Cham, et al., J. Clin. Apheresis, Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals, 10, 61-69. (1995)	
	145	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
	146	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by	
		Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	147	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49, 109-113. (1973)	
	148	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and	_
	140	Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
	149	Cooper, Drugs Aging, Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy , 20 (6), 399-418. (abstract only) (2003)	
	150	Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using	
		the duck hepatitis B model , 22, 119-130. (abstract only) (June 1996)	
	151	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by	_
		Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	

1			
Examiner		Date	
Signature		Considered	
L	<u> </u>		

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/796,691 Filing Date March 8, 2004 INFORMATION DISCLOSURE First Named Inventor Bellotti STATEMENT BY APPLICANT Group Art Unit 1614 (use as many sheets as necessary **Examiner Name** Not yet Assigned Sheet of | 9 Attorney Docket Number 13131-0331 (44378/293531)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Т
Examiner Initials	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	152	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH:	
	į	First Clinical Application of the HELP System, 65, 161-168. (1987)	
	153	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose	
		Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	
	154	Feinstone, et al., Infection and Immunity, Inactivation of Hepatits B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-	
		821. (August 1983)	
	155	Golde et al., Drug Discovery Today, Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's	
		Disease, 6 (20), 1049-1055. (abstract only) (October 15, 2001)	
	156	Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28.	
		(1994)	
	157	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as	
		Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
	158	Klimov, et al., Kardologiia, Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized	
]	Plasma into the Body as a Possible Means to Treat Atherosclerosis [translation], 18, 23-29. (1978)	
	159	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid	
		Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
-	160	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in	
		Hypercholesteraemic Chickens after Treatment with a Newly Developed Extracorpreal Lipid Elimination. (May 13, 1992)	
	161	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in	
		Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
	162	Koudinov et al., Clin Chim Acta, Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein:	1
		Association with Apolipoprotein and Lipids, 270 (2), 75-84. (abstract only) (February 23, 1999)	
	163	Koudinov et al., Cell Biol Int., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, 21	
		(5), 265-71. (abstract only) (May 1997)	

1			
	-		
	Examiner	Date	
	Signature	Considered	
	•	Considered	I

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached. ,

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known		
Substitute for Form 1449/A/PTO				Application Number	10/796,691	
INFORMATION DISCLOSURE				Filing Date	March 8, 2004	
				First Named Inventor	Bellotti	
	STATEME	ENTI	BY APPLICANT	Group Art Unit	1614	
(use as many sheets as necessary			neets as necessary	Examiner Name	Not yet Assigned	
Sheet	8	of	9	Attorney Docket Number	13131-0331 (44378/293531)	

	1	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	ſ
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	164	Koudinov et al., Biochem Biophys Res Commun, Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in	
		Human Cerebrospinal Fluid: Association with High Density Lipoproteins, 223 (3), 592-7. (abstract only) (June 25, 1999)	
	165	Koudinov et al., Science, Cholesterol's Role in Synapse Formation, 294, 2213. (November 9, 2001)	
	166	Koudinova et al., Soc. Neuroscience Abstract Viewer and Itinerary Planner, Amyloid Beta, Neural Lipids, Cholesterol and	
		Alzheimer's Disease - Abstract No, 21.10. (2002)	
	167	Lipid Sciences, http://www.lipidsciences.com/technology.html, Lipid Technology, 1-4. (August 25, 2001)	
	168	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-	
		Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
	169	Mauch et al., Science, CNS Synaptogenesis Promoted by Glia-Derived Cholesterol, 294, 1354-1357. (November 9, 2001)	
	170	Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994)	
	171	Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain	
		Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992)	
	172	Ngu, Medical Hypotheses, The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune	
		response to the virus, 48, 517-521. (1997)	
	173	Parker, et al., Proceedings of the National Academy of Sciences, Plasma High Density Lipoprotein is Increased in Man When	
	•	Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis, 83, 777-781. (1986)	
	174	Refolo et al., Soc. Neuroscience Abstracts, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, 27	
		(2), 1518. (abstract only) (2001)	
	175	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in	
		Plasma or Serum, 13, 769-772. (1967)	

Examiner Signature	Date Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

			reduction Act of 1999, no persons are re	Complete if Known		
Substitute for Form 1449/A/PTO				Application Number	10/796,691	
INFORMATION DISCLOSURE				Filing Date	March 8, 2004	
				First Named Inventor	Bellotti	
,	STATEN	MENT	BY APPLICANT	Group Art Unit	1614	
(use as many sheets as necessary			neets as necessary	Examiner Name	Not yet Assigned	
Sheet	9	of	9	Attorney Docket Number	13131-0331 (44378/293531)	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	176	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human	
		Mononuclear Leukocytes, 20, 413-416. (1979)	
	177	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35,	
		41-49. (1980)	
	178	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia, 1,	
		1208-1211. (1975)	
	179	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic,	
		Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)	
	180	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol	
		extraction, 24, 666-669. (1983)	
	181	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial	
		Hypercholesterolemia, 5, 613-622. (1985)	
	182	Yoshidome et al., Artif Organs, Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density	
		Lipoprotein Apheresis, 22 (2), 144-148. (1998)	
	183	Zetia, http://www.zetia.com/ezetimbe/zetia/hcp/product_highlights/index.jsp, Zetia (ezetimibe), 1-2. (August 18, 2003)	
	184	Zetia, http://www.zetia.com/ezetimibe/zetia.hcp/mechanism_of_action/index.jsp, Zetia: Compliments Statin with a Unique	-
		Mechanism, 1-2. (August 18, 2003)	
			-
			<u> </u>
Examiner		Date	

Examiner	Į.	Date	
Signature		Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.